NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $0.66 +0.02 (+2.82%) Closing price 09/16/2026 04:00 PM EasternExtended Trading$0.64 -0.02 (-2.77%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Onconetix Stock (NASDAQ:ONCO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Onconetix alerts:Sign Up Key Stats Today's Range$0.64▼$0.6950-Day Range$0.61▼$1.0252-Week Range$0.59▼$209.50Volume122,847 shsAverage Volume593,789 shsMarket Capitalization$2.91 millionP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. Read More Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingOnconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageOnconetix has only been the subject of 1 research reports in the past 90 days.Read more about Onconetix's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.86.Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Onconetix's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.85% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently increased by 10.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.91 News SentimentOnconetix has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Onconetix this week, compared to 2 articles on an average week.Search Interest2 people have searched for ONCO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have not sold or bought any company stock.Percentage Held by Insiders0.27% of the stock of Onconetix is held by insiders.Percentage Held by Institutions23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCO Stock News HeadlinesOnconetix, Inc.: CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionSeptember 15 at 10:08 AM | finanznachrichten.deOnconetix Provides Up To $5 Mln Bridge Financing To RealbotixSeptember 15 at 10:08 AM | rttnews.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.September 17 at 1:00 AM | Priority Gold (Ad)Onconetix Provides $2.5 Million Bridge Financing to Realbotix Ahead of Pending AcquisitionSeptember 14 at 1:30 PM | quiverquant.comQCORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionSeptember 14 at 1:00 PM | globenewswire.comOnconetix Secures Bridge Financing for Realbotix AcquisitionSeptember 14 at 11:50 AM | tipranks.comOnconetix, Inc.: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionSeptember 14 at 9:57 AM | finanznachrichten.deOnconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionSeptember 14 at 8:30 AM | globenewswire.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $78.00 at the start of the year. Since then, ONCO stock has decreased by 99.1% and is now trading at $0.6634. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($4,505.00) by $4,503.72. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.02 million. Onconetix had a negative net margin of 1,575.89% and a negative trailing twelve-month return on equity of 91.95%. When did Onconetix's stock split? Onconetix's stock reverse split on Friday, May 22nd 2026.The 1-10 reverse split was announced on Tuesday, May 19th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 21st 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Onconetix IPO? Onconetix (ONCO) raised $20 million in an initial public offering (IPO) on Thursday, February 17th 2022. The company issued 2,222,222 shares at $8.00-$10.00 per share. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include Qualcomm (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings8/13/2026Today9/17/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ONCO's financial health is in the Red zone, according to TradeSmith. ONCO has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)$248.12 Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.03 million Net Margins-1,575.89% Pretax Margin-1,575.89% Return on Equity-91.95% Return on Assets-53.76% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.14 Sales & Book Value Annual Sales$810 thousand Price / Sales3.59 Cash FlowN/A Price / Cash FlowN/A Book Value$505.29 per share Price / Book0.00Miscellaneous Outstanding Shares4,380,000Free Float4,368,000Market Cap$2.91 million OptionableN/A Beta2.68 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ONCO) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe IRA Mistake That Could Cost Americans 55+ Thousands in 2026JPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
